The largest database of trusted experimental protocols

15 protocols using ddavp

1

Pharmacological Modulation of Renal Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
mpkCCD cells (a contribution from Alain Vandewalle, Paris) were cultured in modified DM medium as previously described41 (link),42 (link) and were seeded on semipermeable filters (Transwell 0.4-μm pore size, 4.67 cm2; Corning Costar). The cells were cultured for 5 days, following which they were serum-starved and hormone-deprived for 12 h. The culture medium was changed daily. Tolvaptan (LKT Laboratories) (10–200 μM), L-sulforaphane (Sigma-Aldrich) (10 μM), ML385 (Selleck) (50 μM), dDAVP (Sigma-Aldrich) (1 nM), GSK2606414 (Sigma-Aldrich) (5 μM), thapsigargin (Sigma-Aldrich) (1 μM), and bardoxolone methyl (Cayman Chemical) (1–50 nM), and mozavaptan (Cayman Chemical) (100 μM) were applied to the basolateral side of the mpkCCD cells. The H9C2 cells were cultured in DMEM (Nacalai Tesque) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin, and 0.1 mg/mL streptomycin. On reaching 70–80% confluence, cells were exposed to Tolvaptan (200 μM), L-sulforaphane (10 μM), and dDAVP (Sigma-Aldrich) (1 nM). The renal proximal tubule-derived HK-2 cells were cultured in modified DM medium with 10% fetal calf serum, 100 U/ml penicillin, and 0.1 mg/mL streptomycin. HK2 cells were treated with Tolvaptan (200 μM), L-sulforaphane (10 μM), and dDAVP (Sigma-Aldrich) (1 nM) at 90–95% confluence. All reagents were solved with dimethyl sulfoxide (DMSO).
+ Open protocol
+ Expand
2

Osmotic Demyelination Syndrome: Desmopressin-Induced Animal Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
ODS was induced according to an adapted protocol [98 (link)]. Briefly, an osmotic minipump (Model 1007D, Charles River Laboratories, Germany) filled with desmopressin (dDAVP, 10 µg/ml, Sigma Aldrich, USA) was implanted subcutaneously caudal to the shoulder blade (day 0). Standard chow was switched to low-sodium liquid diet (EF15710-10 EF R/M AIN 76A, Ssniff, Germany), fed ad libitum during hyponatremia. At day 6, i.p. injection of sodium chloride solution (1 M, 1 ml per 100 g body weight) was used to increase serum sodium levels close to normonatremia. After sodium correction, food was switched back to standard pellet chow. At days 0 and 6, blood sodium levels were measured. All animals were monitored daily and brain tissue was harvested after 3 (n = 4), 4 (n = 3), 6 (n = 4), 7 (n = 3), 13 (n = 5), 14 (n = 2) and 21 (n = 6) days post correction (dpc). Untreated age-matched rats were used as healthy controls (n = 5).
+ Open protocol
+ Expand
3

cAMP Measurement in Cell Stimulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were stimulated for 15 min with dDAVP (1 nM or 1 μM, Sigma) or 25 μM forskolin (Sigma) dissolved in DMSO in the presence of 3-isobutyl-1-methylxanthine (IBMX). Controls were DMSO + IBMX. Total cAMP levels were measured using a commercially available cAMP enzyme immunoassay kit (Sigma).
+ Open protocol
+ Expand
4

Xenograft Model of Renal Cell Carcinoma

Check if the same lab product or an alternative is used in the 5 most similar protocols
Athymic Nude-Foxn1nu mice (Nu/Nu mice from Envigo/Harlan), female, 7–8 weeks old, and weighing ~25 g were subcutaneously injected with 1 × 106 Caki1 cells in 100 µL of DMEM medium on the right flank. When palpable tumors appeared, tumor volumes were measured using calipers (Tumor volume = (length × width2)/2). When the tumor volumes reached ~80–100 mm3, mice were randomized and assigned to 3 groups and administered vehicle (saline), OPC31260 (30 mg/Kg BWt), or dDAVP (1 μg/Kg BWt, IP, daily for 28 days) purchased from Sigma Millipore (St. Louis, MO, USA). Body weights and tumor volumes were measured every other day. At sacrifice, tumors were collected, weighed, and fixed in 4% paraformaldehyde for immunostaining. All animal studies were performed according to the protocols approved by the University of Kansas Medical Center Institutional Animal Care and Use Committee.
+ Open protocol
+ Expand
5

Thick Ascending Limb Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols
Thick ascending limbs from 6- to 8-weeks old male C57BL/6J-HpnHlb320/Hlb320 or C57BL/6J-HpnWT/WT mice were isolated and cultured as reported previously19 (link). Thick ascending limbs were manually collected under a light microscope and seeded on fibronectin-coated (Corning Inc., Corning, NY) 96-well plastic plates (Thermo Fischer Scientific) containing a culture medium based on DMEM:F1219 (link) (Thermo Fischer Scientific) and placed in a humidified chamber at 37 °C and 5% CO2. When cellular outgrow reached near confluence, cells were passed using 0.05% Trypsin-EDTA (Thermo Fischer Scientific) to fibronectin and collagen-coated 0.33 cm2 PTFE filter membranes (Corning Inc., Corning, NY). After a confluent monolayer of cells was reached, supplemented FBS (Thermo Fischer Scientific) was reduced from 2% to 0.1% (v/v) to allow maximal differentiation. Cells were treated with 100 µM bumetanide (Sigma-Aldrich) to the apical side, with 0.1 µM ddAVP (Sigma-Aldrich) to the basolateral side or with 2.5 µg/mL tunicamycin (Sigma-Aldrich) to the apical and basolateral side. Transepithelial voltage measurements were performed using chopstick electrodes (STX2, World precision instruments, Sarasota, FL) according to manufacturer’s instructions.
+ Open protocol
+ Expand
6

Culturing mpkCCD Cells for Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
mpkCCDcl4 cells (gift from Alain Vandewalle, Paris) were cultured as previously described25 (link). The mpkCCD cells were seeded on semipermeable filters (Transwell, 0.4-µm pore size; Corning Costar). For immunofluorescence and western blot analysis, 0.33-cm2 and 4.67-cm2 filters were used, respectively. The mpkCCD cells were cultured for 5 days, with changes of the medium daily. St-Ht31 (Promega Corporation, Madison, WI, USA), St-Ht31P (Promega Corporation), FMP-API-1 (Sigma–Aldrich Corporation, St. Louis, MO, USA), FMP-API-1/27, FMP-API-1/28, dDAVP (Sigma–Aldrich Corporation), and H89 (Sigma–Aldrich Corporation) were applied to the basolateral side of the mpkCCD cells.
+ Open protocol
+ Expand
7

Vasopressin Receptor Signaling Modulators

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tolvaptan (OPC41061, 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino) benzoyl]-2,3,4,5- tetrahydro-1H-1-benzazepine), OPC31260 (Mozavaptan, 5-(Dimethylamino)-1-[4-(2-methylbenzamido)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine hydrochloride), 8-Br-cAMP, and dDAVP (1-desamino-8-d-arginine vasopressin) were from Sigma Millipore (St. Louis, MO). Primary antibodies were purchased for phosphorylated cAMP response element binding protein (pCREB) (#9198S), CREB (#9197S), Ki-67 (#9449S), phosphorylated extracellular signal regulated kinase (pERK1/2) (#9101S), and ERK1/2 (#SC-94) from Cell Signaling Technology (Danvers, CA, USA); vascular endothelial growth factor (VEGF) (#SC-7269) and GAPDH (#SC-47724) from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and V2R (#V5514) from Sigma Millipore (St. Louis, MO, USA) and CD31 (#ab28364) from Abcam (Cambridge, MA, USA). Secondary antibodies were from Dako (Carpinteria, CA) and ECL reagent was from Perkin Elmer (Waltham, MA, USA).
+ Open protocol
+ Expand
8

Preparation and Formulation of Pharmacological Agents

Check if the same lab product or an alternative is used in the 5 most similar protocols
(R)-6-Chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol hydrobromide (FD; Sigma, St. Louis, MO) was dissolved in the vehicle that consisted of sterile 20% (v/v) propylene glycol:80% (v/v) 0.9% (w/v) sodium chloride (saline). (LPS; Endotoxin) from Escherichia coli (E. coli) and [deamino-Cys, D-Arg8]-vasopressin (DDAVP; Sigma, St. Louis, MO) were dissolved in 0.9% (w/v) sodium chloride (saline) at 2 mg/ ml and 10 μg/ml, respectively. The PCO (ZD6169) was formulated as a suspension in 0.5% (w/v) hydroxypropyl methylcellulose (HPMC) solution containing 0.1% (w/v) aqueous polysorbate 80. Dopamine (DA) was dissolved in 0.9% (w/v) sodium chloride (saline).
+ Open protocol
+ Expand
9

Regulation of Renal Function by dDAVP

Check if the same lab product or an alternative is used in the 5 most similar protocols
All procedures were accomplished in agreement with the Danish National Guidelines for the care and handling of experimental animals and the published guidelines of the National Institutes of Health. The protocols were approved by the Institute of Clinical Medicine, Aarhus University, according to the licenses for the use of experimental animals issued by the Danish Ministry of Justice (Approval number 2015-15-0201-00658). Studies were performed on adult male Wistar rats with a starting weight of 200–225 g. Animals were maintained on a standard rodent diet (Altromin, Lage, Germany) and had free access to tap water. During the experiments, rats were housed in groups of two per cage, with a 12:12 h light–dark cycle, a temperature of 21 ± 2 °C, and a humidity of 55 ± 2%.
Five rats were treated with subcutaneous injection of 1 ng dDAVP (Sigma-Aldrich, Glostrup, Denmark) in 200 µl saline/animal, and five vehicle-treated rats served as controls. After 30 min, the rats were killed, and the kidneys were processed as described below.
+ Open protocol
+ Expand
10

Vasopressin Receptor Signaling Modulators

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tolvaptan (OPC41061, 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino) benzoyl]-2,3,4,5- tetrahydro-1H-1-benzazepine), OPC31260 (Mozavaptan, 5-(Dimethylamino)-1-[4-(2-methylbenzamido)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine hydrochloride), 8-Br-cAMP, and dDAVP (1-desamino-8-d-arginine vasopressin) were from Sigma Millipore (St. Louis, MO). Primary antibodies were purchased for phosphorylated cAMP response element binding protein (pCREB) (#9198S), CREB (#9197S), Ki-67 (#9449S), phosphorylated extracellular signal regulated kinase (pERK1/2) (#9101S), and ERK1/2 (#SC-94) from Cell Signaling Technology (Danvers, CA, USA); vascular endothelial growth factor (VEGF) (#SC-7269) and GAPDH (#SC-47724) from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and V2R (#V5514) from Sigma Millipore (St. Louis, MO, USA) and CD31 (#ab28364) from Abcam (Cambridge, MA, USA). Secondary antibodies were from Dako (Carpinteria, CA) and ECL reagent was from Perkin Elmer (Waltham, MA, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!